Alternatives to mainstream medications are a topic of much discussion, including disparities among therapists with regard to race.”Who Will Benefit From Psychedelic Medicine?These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.MAPS is currently studying MDMA-assisted psychotherapy as a method of treating PTSD. The clinical trials are in Phase 3 — the last stage before approval from the U.S. Food and Drug Administration — and MAPS, which has been working toward this moment since its inception as a research and advocacy organization in 1986, has been preparing for a post-approval world.Before the Cultural Trauma workshop in Kentucky, MAPS had trained 285 therapists, with the idea that — while they can’t legally practice yet — they will be ready to open their doors once approval is final. But fewer than 10 percent of those trained were people of color. If MAPS wanted therapists to treat clients of color, they would need to train therapists of color.”More from Washington Post: https://wapo.st/2S3ycfA